Novartis
Basel, Switzerland
East Hanover, New Jersey, United States
with other locations globally
United States
1966 articles with Novartis
-
The FDA initiated the partial hold after Novartis’ subsidiary AveXis, the developer of the therapy, told health authorities it found dorsal root ganglia mononuclear cell inflammation associated with the treatment in preclinical animal studies.
-
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
-
The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.
-
The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
-
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
7/20/2021
Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and others to address root causes of disparities in health and education
-
The Biotech Bay region is home to 3,418 life sciences companies, and 96,574 employees making an average of $151,076.
-
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
-
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
7/6/2021
Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors.
-
Elliott said the GSK has underperformed for more than a decade and called for the board to select leaders who have significant background and experience in biopharma and health care.
-
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
-
This program limits the prices drug manufacturers can charge for therapies sold to specific healthcare facilities, including public hospitals and community health centers.
-
New data shows Zolgensma, Novartis’ gene therapy for spinal muscular atrophy, has the potential to be used presymptomatically in juveniles.
-
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.
-
Eli Lilly and Company announced Tuesday the launch of a head-to-head study to compare once-monthly injectable Emgality® (galcanezumab-gnlm) with Nurtec® ODT (rimegepant) for the prevention of migraine.
-
Novartis flexed its clinical muscles over the weekend, announcing results from multiple studies including different types of cancer and kidney disease.
-
Clinical Catch-Up: June 1-6
6/7/2021
With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news. -
Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
6/4/2021
Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001)
-
Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
6/4/2021
Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14)1-
-
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
-
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
6/3/2021
Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radiological therapy.